Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
134 hedge funds and large institutions have $1.2B invested in Amicus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 39 reducing their positions, and 23 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
54% more capital invested
Capital invested by funds: $780M → $1.2B (+$424M)
27% more call options, than puts
Call options by funds: $9.28M | Put options by funds: $7.29M
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
21% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 39
8.05% more ownership
Funds ownership: 110.21% → 118.25% (+8%)
1% less funds holding
Funds holding: 135 → 134 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$75.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.4M |
| 3 |
Morgan Stanley
New York
|
+$19.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$10.3M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$10.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.04M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.9M |
FOLD Hedge Fund Activity: Q1 2017 in Review
134 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2017, worth a combined $1.2B — up 54% from $780M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FOLD positions and 23 closed out — a net gain of 5 holders — while 47 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $75.6M. The largest seller was AllianceBernstein, cutting an estimated $10.3M.
- 134 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2017, down from 135 in Q4 2016.
- Funds reported $1.2B of Amicus Therapeutics stock for Q1 2017, up 54% quarter-over-quarter.
- 28 funds opened new Amicus Therapeutics positions in Q1 2017 and 23 closed out, a net change of +5 holders.
- The largest Amicus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $75.6M added.
- The largest Amicus Therapeutics seller in Q1 2017 was AllianceBernstein, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2017.